« Return to News | CROs/Service Providers

Parexel Profits Down in Q2, Revenues Up

Tuesday, January 27, 2009 08:00 AM

Parexel’s second quarter financial results, released late Monday, reflect the ill effects of negative foreign exchange rates and a recently terminated contract.

The Waltham, Mass.-based contract research organization (CRO) reported an increase in service revenues for the second quarter of 2009 compared with the prior year, but year-over-year profits were cut by more than half from $11.5 million in the second quarter 2007 to $5.2 million for the quarter ended December 31, 2008.

Service revenues increased 15.6% to $275.8 million for the second quarter of fiscal year 2009, up from $238.7 in the prior year period.

"With regard to our outlook for the current calendar year, I remain cautiously optimistic. While we may experience a slow-down in the small biopharma client segment due to the current condition of the financial markets, I believe that this impact may be offset by an increase in outsourcing levels from larger clients,” said Parexel chairman and CEO Josef von Rickenbach in a company release.

Earlier this month, funding difficulties caused the sponsor of a large clinical trial to pull out of a contract with Parexel, and the sponsor subsequently filed for bankruptcy protection. Parexel terminated its contract with the client and recorded $15 million in pre-tax reserves in the second quarter for anticipated wind-down costs and bad debt expense related to impaired accounts receivable.

Parexel's share prices were up 26% to $9.30 in morning trading.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.